#3910
Integrative molecular analysis of lung neuroendocrine neoplasms with different Ki-67 indices identifies a molecular transition group between low- and high-grade neoplasms
Introduction:
In the 2021 World Health Organization (WHO) classification of lung cancers, lung neuroendocrine neoplasms (LNENs) are classified as low-grade, intermediate-grade and high-grade based on mitotic count but not Ki-67 index, as for GEP-NENs.
Conference:
Presenting Author:
Authors:
Simbolo M,
Centonze G,
Ali G,
Grillo F,
Sabella G,
Keywords:
lung neuroendocrine tumor,
NET grade 3,
next generation sequencing,
transcriptomics,
#3347
Broncho-pulmonary combined large-cell neuroendocrine carcinomas (Co-LCNEC): More than a hybrid neoplasm
Introduction:
The current WHO classification of lung neoplasms defines combined large cell neuroendocrine carcinomas (CoLCNECs) as the association of an LCNEC with a recognizable component of adenocarcinoma, squamous cell carcinoma, small cell carcinoma or, rarely, with atypical carcinoid.
Conference:
Presenting Author:
Authors:
Simbolo M,
Centonze G,
Giudice L,
Ciaparrone C,
Grillo F,
Keywords:
neuroendocrine carcinoma,
combined large cell neuroendocrine carcinoma,
next generation sequencing,
transcriptomics,
#3346
Molecular characterization of a multi-institutional pan-lung cohort using integrative genomic and transcriptomic analysis
Introduction:
Lung cancer represents one of the most common neoplasm worldwide and leading cause of cancer mortality. World Health Organization (WHO) show six major histotypes (AC, LCNEC, SCLC, TC, ADC, SQC) dividing them mainly in two lineages (neuroendocrine and non-neuroendocrine) that can also combine each other.
Conference:
Presenting Author:
Authors:
Simbolo M,
Centonze G,
Giudice L,
Ali G,
Ciaparrone C,
Keywords:
neuroendocrine carcinoma,
next generation sequencing,
transcriptomics,
lung cancer,
combined-lung cancer,
#3345
Integrative molecular analysis of combined small-cell lung carcinoma reveals EGFR and KRAS mutational analysis as the theragnostic tools in whole small cells lung carcinoma landscape
Introduction:
Combined small-cell lung cancer (C-SCLC) are composed of SCLC admixed with a non-small-cell cancer component. They currently receive the same treatment as SCLC. The recent evidence that SCLC may belong to either of 2 lineages, neuroendocrine or non-neuroendocrine, with different vulnerability to specific cell death pathways such as ferroptosis, opens new therapeutic opportunities also for C-SCLC.
Conference:
Presenting Author:
Authors:
Simbolo M,
Centonze G,
Ali G,
Ciaparrone C,
Grillo F,
Keywords:
Combined small cell lung carcinoma,
small cell lung cancer,
neuroendocrine carcinoma,
next generation sequencing,
transcriptomics,
